We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
deepak shukla
Apr 09, 2015
pt is aymptomatic CRPC so sipeucel-t and abiraterone are resonable options at present ...following progression on these initially docetaxel and laterenzulatamide & cabazitaxel can be used.
Charles Maack
Apr 21, 2015
With cancer having progressed to Gleason 5=5.10, sipeucel-T unlikely to have much effect. Continued Lupron with added dutasteride/Avodart to inhibit T conversion to DHT and enzalutamide to block androgen receptors could be a reasonable pre-chemo consideration, with docetaxel/carboplatin as an alternate consideration then followed by either enzalutamide or abiraterone. In the meantime, patient should have CTC ;checked as well as determining if AR-V7 variant is present, since if present neither enzalutamide nor abiraterone are going to be effective. Cabazitaxel remains available as does alpharadin/Radium 223 if mets become painful..
Apr 25, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Eugene
Pietzak
MD
deepak shukla
Apr 09, 2015
Charles Maack
Apr 21, 2015
Apr 25, 2024
Pending Moderator approval.